Administration of OLE-JGF could effectively ameliorate obesity and related metabolic disorders, which may be associated with the inhibition of hepatic lipogenesis and stimulation of mitochondrial biogenesis controlled by the liver kinase B1 (LKB1)-PGC-1α axis. Here, STK11 is linked to metabolic disease.